Healthtech Startups

Equitas Medical builds clinic management infrastructure in Japan, offering clinic operation support, business succession support, and medical digital transformation to maintain continuous care between hospitals and local communities. It targets clinic owners and healthcare providers to address gaps in post-discharge follow-up care.

1 investor

Oncolys develops viral therapy drugs and treatments for cancer and severe viral infections, with a focus on oncolytic viruses and rare diseases. The company operates a hybrid business model combining licensing partnerships with pharmaceutical firms and direct commercialization of its own therapies.

1 investor

Carbgem (カーブジェン株式会社) is a Japanese company that applies generative AI, image AI, and cloud technology to build R&D and operational solutions, including drug discovery support, image and tissue analysis, quality control, medical document assistants, and diagnostic support. It serves life sciences, healthcare, consumer goods/distribution, manufacturing/infrastructure, and public/administrative sectors to address labor shortages, work standardization, and real-time decision-making.

1 investor

Callisto builds a medical imaging data infrastructure platform to support AI research and drug development by collecting, anonymizing, and structuring medical image data from Japanese healthcare facilities for use in AI model development and clinical research.

1 investor

Xirapha (operating under WeeMex Inc.) develops and operates cloud-based electronic health record systems and digital healthcare services for medical providers. The company's primary offering is Kirin Karute, a free cloud-based electronic medical records platform.

1 investor

Clipla develops cloud-based electronic medical record systems for specialized medical practices including ophthalmology, obstetrics/gynecology, and otolaryngology.

1 investor

ClinCloud provides cloud-based solutions for collecting clinical trial data, aimed at improving the efficiency of data collection in drug development for pharmaceutical companies and research institutions. It also runs a CRO business covering data management and statistical analysis, and is based in Tokyo, Japan.

1 investor

Cozre operates a media and market research platform serving parents and caregivers in Japan, providing data-driven insights into parenting trends, consumer behavior, and family-related products and services. The company has grown from a small media outlet to a community of over 900,000 member households, offering awards, market research reports, and marketing research services focused on the parenting and women's career development sectors.

1 investor

Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.

1 investor

GeCS provides a mobile application for patients to manage and understand their medical information, prescriptions, and treatment history. The company aims to ensure equitable access to appropriate healthcare by simplifying the patient journey and reducing information gaps between medical professionals and patients.

1 investor

GENEX, Inc. operates a data platform for genomic and healthcare information, letting individuals obtain and manage their whole-genome data for personal health management, medical access, and medical research. The company also offers whole-genome acquisition/management collaborative research and agency support services to clients.

1 investor

Joshu develops a healthcare information sharing platform that connects care providers and facilities to support integrated community-based care systems.

1 investor

CellGen Tech develops cell-based medicines for rare and intractable diseases by engineering human adipose cells to produce therapeutic proteins. The company focuses on treating conditions caused by missing or deficient enzymes and proteins, with partnerships involving university medical experts.

1 investor

Cellspect develops next-generation clinical diagnostic reagents and in-vitro diagnostic products based on deep-tech, covering diagnostic technologies from biomarker discovery to treatment monitoring. It offers open-innovation partnerships with pharmaceutical companies and medical institutions, including point-of-testing and precision oncology products, based in Iwate, Japan.

1 investor

T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.

1 investor

Nagasuna Mayu develops and manufactures silk protein products (sericin and fibroin) for application in cosmetics, healthcare, and materials, along with textile refining machinery. The company operates multiple facilities in Kyoto Prefecture, Japan, focusing on innovation in silk-based biotechnology.

1 investor

Japanese company that develops digital health services focused on epilepsy care, including a seizure-tracking app for families of children with epilepsy and related tools for doctors, pharmacies, and online consultations. It serves epilepsy patients, their families, and healthcare providers in Japan.

1 investor

A Japanese biotech company developing regenerative medicine technology (iBTA / in-Body Tissue Architecture) that grows the patient's own tissue to form implantable structures such as Biotube and Biosheet. Its applications include treatments for conditions like severe diabetic foot ulcers and gangrene.

1 investor

Human Life Code develops and commercializes novel therapeutics in specialty care areas such as cancer, autoimmune diseases, and retinal diseases. The company specializes in research, development, market launch, and lifecycle management of pharmaceutical products and regenerative medicine products.

1 investor

PharmaBio is Japan's first contract development and manufacturing organization (CDMO) for regenerative medicine and cell-based therapeutics. The company provides regulatory development support and manufacturing services for cell and tissue-derived pharmaceuticals.

1 investor

Feed operates business-to-business e-commerce sites selling consumables, medical devices, and pharmaceuticals for dental clinics, animal hospitals, and nursing/medical care facilities. It supplies infection-control products, gloves, masks, and specialized items to healthcare and elderly-care providers in Japan.

1 investor

Physiologas develops technology to innovate healthcare and improve patient and family wellbeing. The company operates in the medical technology sector, based in Japan.

1 investor

Kamui Pharma develops therapeutic compounds derived from probiotics for treating inflammatory bowel disease and other diseases. The company conducts drug discovery research and clinical trials focused on novel bioactive molecules.

1 investor

PorMedTec develops transplantable organs and tissues using genetically modified pigs for manufacturing and commercializing as regenerative medicine products. The company targets patients and healthcare systems facing severe organ shortages by providing alternatives to dialysis and other symptom-based treatments.

1 investor